Lipoproteins will play a crucial role in assessing the risk of cardiovascular disease (CVD).
Based on the firm’s 600 MHz AVANCE IVDr in vitro diagnostics research platform, the new Bruker IVDr lipoprotein subclass analysis (B.I.-LISA) module offers potential for in-depth clinical research in CVD.
The new nodule was developed in partnership with Germany Greifswald University’s institute of clinical chemistry and laboratory medicine head professor Nack.
Provided as a new option for Bruker’s IVDr-by-NMR platform, the B.I.-LISA module on the 600 MHz AVANCE IVDr NMR platform can screen up to 150 samples per day in full automation.
It helps in report generation of 114 lipoprotein related parameters, simplifying the measurement procedure, in addition to offering high throughput with highest information content.
The new module is said to determine cholesterol, free cholesterol, phospholipids, triglycerides, apolipoproteins A1, A2, B and particle numbers for plasma and serum lipoprotein main and subclasses.
According to the company, the B.I.-LISA test fulfills the NCEP (US National Cholesterol Education Program) requirements used worldwide in analytical service labs for lipoprotein main fractions with regard to precision and accuracy.
Nack said: "Lipoproteins play an important role in the body’s function, and further understanding of their subclasses brings us one step closer to understanding and possibly preventing cardiovascular and related diseases.
"With Bruker’s IVDr-by-NMR profiling module B.I.-LISA, we can extract information on the main classes of lipoproteins and more importantly, their subclasses, in plasma."
Image: AVANCE-IVDr systems at St. Mary’s Clinical Phenome Center in London, UK. Photo: courtesy of Bruker Corporation.
